Classification ![]() |
|
Compound class | Peptide or derivative |
Approved drug? | Yes (FDA and EMA (2014)) |
International Nonproprietary Names ![]() |
|
INN number | INN |
8829 | albiglutide |
Synonyms ![]() |
Eperzan® | GSK716155 | Tanzeum® |
Comments |
Albiglutide is recombinant protein engineered by fusing the gene for glucagon-like peptide 1 (GLP-1; an incretin secreted in the gut) with the gene for human albumin. In this case the GLP-1 appears to contain an amino acid substitution (Ala to Glu at the C-terminal) directly adjacent to the dipeptidyl peptidase-4 (DPP-4; the enzyme responsible for in vivo degradation of GLP-1) hydrolysis site, which renders the peptide resistant to cleavage by this enzyme [3,5]. In conjunction with the fusion to albumin [2] this drug has an extended half-life compared to other approved drug GLP-1 mimetics. |
Database Links ![]() |
|
Specialist databases | |
IMGT/mAb-DB | 397 |
Other databases | |
ChEMBL Ligand | CHEMBL2107841 |
GtoPdb PubChem SID | 178103958 |
Search PubMed clinical trials | albiglutide |
Search PubMed titles | albiglutide |
Search PubMed titles/abstracts | albiglutide |
Wikipedia | Albiglutide |